07:54 AM EDT, 08/26/2025 (MT Newswires) -- Marker Therapeutics ( MRKR ) said Tuesday its investigational therapy MT-601 achieved a 66% objective response rate in patients with relapsed non-Hodgkin lymphoma, and 50% showed a complete response.

In the phase 1 study, eight out of 12 non-Hodgkin lymphoma patients responded to treatment, including six with complete responses, Marker Therapeutics ( MRKR ) said.

In Hodgkin lymphoma patients, seven out of nine patients responded to the treatment, including one with a complete response, the company added.

Marker Therapeutics ( MRKR ) said MT-601 was well-tolerated with no dose-limiting toxicities.

Shares of the company were up more than 23% in Tuesday premarket activity.